CA-NETAPP
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced new capabilities that maximize the potential of generative artificial intelligence (Gen AI) projects and build competitive advantage for users. Customers can now take their AI projects to the next level by combining NetApp’s intelligent data infrastructure with high-performance compute, networking and software from NVIDIA.
Gen AI has captured global attention for its potential to automate tedious tasks, uncover new insights, and drive product innovation. Nearly three out of four companies are already using Gen AI, according to the NetApp 2023 Data Complexity report. To unlock the potential of Gen AI, organizations need secure, high-performance access to data spread across complex hybrid and multicloud environments. NetApp has a long and successful history of expertise in supporting AI with solutions that deliver management simplicity anywhere data lives, provide high performance without requiring new infrastructure silos, and supply trusted, secure data to drive responsible AI.
“NetApp is the intelligent data infrastructure company, with solutions optimized to maximize the potential of our customers’ AI investments,” said Arunkumar Gururajan, Vice President of Data Science & Research at NetApp. “Our unique approach to AI gives customers complete access and control over their data throughout the data pipeline, moving seamlessly between their public cloud and on-premises environments. By tiering object storage for each phase of the AI process, our customers can optimize both performance and costs exactly where they need them. Our unified approach delivers the performance, productivity, and protection customers need to quickly innovate with AI.”
To support companies leveraging Gen AI to improve their operations and strategic decision-making, NetApp released updates to its intelligent data infrastructure capabilities including:
- NetApp AIPod™ is NetApp's AI-optimized converged infrastructure for organizations’ highest priority AI projects, including training and inferencing. NetApp AIPod powered by NVIDIA DGX is now a certified NVIDIA DGX BasePOD solution using NVIDIA DGX H100 systems integrated with NetApp AFF C-Series affordable capacity flash systems to drive a new level of cost/performance while optimizing rack space and sustainability. NetApp AIPod powered by NVIDIA DGX also continues to support NVIDIA DGX A100 systems.
- New FlexPod for AI reference architectures extend the leading converged infrastructure solution from NetApp and Cisco. FlexPod for AI now supports the NVIDIA AI Enterprise software platform. FlexPod for AI can now be extended to leverage RedHat OpenShift and SuSE Rancher. New scaling and benchmarking have been added to support increasingly GPU-intensive applications. Customers can use these new FlexPod solutions as an end-to-end blueprint to efficiently design, deploy, and operate the FlexPod platform for AI use cases.
- NetApp is now validated for NVIDIA OVX systems. NetApp storage combined with NVIDIA OVX computing systems can help streamline enterprise AI deployments, including model fine-tuning and inference workloads. Powered by NVIDIA L40S GPUs, validated NVIDIA OVX solutions are available from leading server vendors and include NVIDIA AI Enterprise software along with NVIDIA Quantum-2 InfiniBand or NVIDIA Spectrum-X Ethernet, and NVIDIA BlueField-3 DPUs. NetApp is one of the first partners to complete this new storage validation for NVIDIA OVX.
To further enhance its AI leadership, NetApp also is announcing revolutionary new cyber-resilience capabilities including one of the first uses of AI/ML embedded in storage to fight ransomware. The new Autonomous Ransomware Protection with AI (ARP/AI) will provide the next generation of machine learning in ONTAP, giving the increased accuracy and performance required to detect and mitigate new, more sophisticated cyber threats.
“AI powers mission-critical use cases in every industry, from healthcare to manufacturing to financial services,” said Tony Paikeday, Senior Director of AI Systems at NVIDIA. “NetApp AIPod certified for NVIDIA DGX BasePOD provides a powerful reference architecture that helps enterprises eliminate design complexity, reduce deployment time frames, and simplify ongoing operations.”
“GenAI has massive potential to help organizations harness their data to uncover business insights and improve operational efficiency,” said Archana Venkatraman, Research Director, Cloud Data Management, IDC. “NetApp has continuously adapted to deliver the services and solutions customers need to effectively manage their data pipelines. These updates further illustrate NetApp’s willingness to evolve and bring innovations to customers that unlock the full potential of AI.”
NetApp delivers a unified approach to infrastructure and data management that eliminates data silos, brings enhanced performance and trusted data protection to customers’ AI turnkey solutions, and helps customers accelerate the time to results for their AI projects.
To learn more about the NetApp offerings to support Gen AI, visit: https://www.netapp.com/artificial-intelligence/
Additional Resources
- Your Data, Your AI, Anywhere: Introducing the NetApp AIPod Now Certified on NVIDIA's DGX H100
- FlexPod: Where Converged Meets Cloud
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305729049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom